Cargando…

Importance and What to Watch Out for De Novo Donor Specific Anti-HLA Antibodies after Kidney Transplantation

Detalles Bibliográficos
Autor principal:	Yang, Chul Woo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Academy of Medical Sciences 2018
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6097070/ https://www.ncbi.nlm.nih.gov/pubmed/30127708 http://dx.doi.org/10.3346/jkms.2018.33.e228

Ejemplares similares

Characteristics and Clinical Significance of De Novo Donor-Specific Anti-HLA Antibodies after Kidney Transplantation
por: Jung, Hee-Yeon, et al.
Publicado: (2018)

The natural history of de novo donor-specific HLA antibodies after kidney transplantation
por: López del Moral, Covadonga, et al.
Publicado: (2022)

Impact of Low-Level Donor-Specific Anti-HLA Antibody on Posttransplant Clinical Outcomes in Kidney Transplant Recipients
por: Lee, Haeun, et al.
Publicado: (2023)

Clinical impact of complement (C1q, C3d) binding De Novo donor-specific HLA antibody in kidney transplant recipients
por: Lee, Hyeyoung, et al.
Publicado: (2018)

Combined Analysis of HLA Class II Eplet Mismatch and Tacrolimus Levels for the Prediction of De Novo Donor Specific Antibody Development in Kidney Transplant Recipients
por: Lee, Hyeyoung, et al.
Publicado: (2022)

An adjustable predictive score of graft survival in kidney transplant patients and the levels of risk linked to de novo donor-specific anti-HLA antibodies
por: Prémaud, Aurélie, et al.
Publicado: (2017)

Living Donor Kidney Transplantation in Patients With Donor-Specific HLA Antibodies After Desensitization With Immunoadsorption
por: Kälble, Florian, et al.
Publicado: (2021)

Impact of Resolved Preformed, Persistent Preformed, and De Novo Anti-HLA Donor-Specific Antibodies in Kidney Transplant Recipients on Long-Term Renal Graft Outcomes
por: Gniewkiewicz, Michal, et al.
Publicado: (2023)

Donor-Specific Anti-HLA Antibodies in Allogeneic Hematopoietic Stem Cell Transplantation
por: Morin-Zorman, Sarah, et al.
Publicado: (2016)

Circulating Donor-Specific Anti-HLA Antibodies Associate With Immune Activation Independent of Kidney Transplant Histopathological Findings
por: Van Loon, Elisabet, et al.
Publicado: (2022)

Clinical significance of de novo donor-specific antibody in kidney transplant recipients with chronic antibody-mediated rejection
por: Park, Woo Yeong, et al.
Publicado: (2021)

Effect of Preformed or De Novo Anti-HLA Antibodies on Function and Graft Survival in Kidney Transplant Recipients
por: de Sousa, Marcos Vinicius, et al.
Publicado: (2018)

Preformed Donor-specific Antibodies Against HLA Class II and Graft Outcomes in Deceased-donor Kidney Transplantation
por: Uffing, Audrey, et al.
Publicado: (2019)

Complement-Binding Donor-Specific Anti-HLA Antibodies: Biomarker for Immunologic Risk Stratification in Pediatric Kidney Transplantation Recipients
por: Sigurjonsdottir, Vaka K., et al.
Publicado: (2022)

Single fixed low-dose rituximab as induction therapy suppresses de novo donor-specific anti-HLA antibody production in ABO compatible living kidney transplant recipients
por: Tomita, Yusuke, et al.
Publicado: (2019)

Incidence and Clinical Significance of De Novo Donor Specific Antibodies after Kidney Transplantation
por: Lionaki, Sophia, et al.
Publicado: (2013)

Clinical significance of donor-specific anti-HLA-DR51/52/53 antibodies for antibody-mediated rejection in kidney transplant recipients
por: Park, Borae Geum, et al.
Publicado: (2019)

The Influence of Immunosuppressive Agents on the Risk of De Novo Donor-Specific HLA Antibody Production in Solid Organ Transplant Recipients
por: O'Leary, Jacqueline G., et al.
Publicado: (2016)

Dynamic Behaviour of Donor Specific Antibodies in the Early Period Following HLA Incompatible Kidney Transplantation
por: Phillpott, Mason, et al.
Publicado: (2022)

Daratumumab for donor-specific anti-HLA antibody desensitization in a case of HLA-mismatched allogeneic stem cell transplantation
por: Ibrahim, Uroosa, et al.
Publicado: (2023)

The Accuracy of Sequence-Specific Oligonucleotide and Real-Time Polymerase Chain Reaction HLA Typing in Determining the Presence of Pre-Transplant Donor-Specific Anti-HLA Antibodies and Total Eplet Mismatches for Deceased Donor Kidney Transplantation
por: Larkins, Nicholas G., et al.
Publicado: (2022)

The Clinical Impact of Anti-HLA Donor Specific Antibody Detection Through First Year Screening on Stable Kidney Transplant Recipients
por: Sharma, Akhil, et al.
Publicado: (2022)

Donor Specific Anti-HLA Antibody and Risk of Graft Failure in Haploidentical Stem Cell Transplantation
por: Kongtim, Piyanuch, et al.
Publicado: (2016)

Donor-specific anti-HLA antibodies in unrelated hematopoietic cell transplantation for non-malignant disorders
por: Woolfrey, Ann, et al.
Publicado: (2018)

De Novo Donor-Specific HLA Antibody Development and Peripheral CD4(+)CD25(high) Cells in Kidney Transplant Recipients: A Place for Interaction?
por: Alberu, Josefina, et al.
Publicado: (2012)

De Novo Donor-Specific HLA Antibodies Developing Early or Late after Transplant Are Associated with the Same Risk of Graft Damage and Loss in Nonsensitized Kidney Recipients
por: Cioni, Michela, et al.
Publicado: (2017)

Association of intraindividual tacrolimus variability with de novo donor-specific HLA antibody development and allograft rejection in pediatric kidney transplant recipients with low immunological risk
por: Baghai Arassi, Maral, et al.
Publicado: (2022)

Complement Binding Anti-HLA Antibodies and the Survival of Kidney Transplantation
por: Muñoz-Herrera, Claudia M., et al.
Publicado: (2023)

Differential effects of donor‐specific HLA antibodies in living versus deceased donor transplant
por: Kamburova, E. G., et al.
Publicado: (2018)

Donor specific HLA antibody in hematopoietic stem cell transplantation: Implications for donor selection
por: Krummey, Scott M., et al.
Publicado: (2022)

Association of non-HLA antibodies against endothelial targets and donor-specific HLA antibodies with antibody-mediated rejection and graft function in pediatric kidney transplant recipients
por: Fichtner, Alexander, et al.
Publicado: (2021)

Clinical Significance of Shared T Cell Epitope Analysis in Early De Novo Donor-Specific Anti-HLA Antibody Production After Kidney Transplantation and Comparison With Shared B cell Epitope Analysis
por: Tomosugi, Toshihide, et al.
Publicado: (2021)

Pretransplant Donor-Specific Anti-HLA Antibodies and the Risk for Rejection-Related Graft Failure of Kidney Allografts
por: Betjes, Michiel G. H., et al.
Publicado: (2020)

Erratum: Clinical significance of shared T cell epitope analysis in early de novo donor-specific anti-HLA antibody production after kidney transplantation and comparison with shared B cell epitope analysis
Publicado: (2022)

Development of De Novo Donor-specific HLA Antibodies and AMR in Renal Transplant Patients Depends on CYP3A5 Genotype
por: Friebus-Kardash, Justa, et al.
Publicado: (2021)

Imlifidase for the treatment of anti‐HLA antibody‐mediated processes in kidney transplantation
por: Huang, Edmund, et al.
Publicado: (2021)

Class and Kinetics of Weakly Reactive Pretransplant Donor-specific HLA Antibodies Predict Rejection in Kidney Transplant Recipients
por: Morrison, Alexander H., et al.
Publicado: (2019)

Watch out, Someone is Watching You!
por: Mehta, Yatin, et al.
Publicado: (2019)

Combination treatment of rituximab and donor platelets infusion to reduce donor‐specific anti‐HLA antibodies for stem cells engraftment in haploidentical transplantation
por: Zhang, Rongli, et al.
Publicado: (2020)

Post-transplant donor-specific anti-HLA antibodies with a higher mean fluorescence intensity are associated with graft fibrosis in pediatric living donor liver transplantation
por: Goto, Ryoichi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9rq8qrcek5asisiqonkggsmmhs